vimarsana.com

புதியது ப்ராடக்ட்ஸ் மற்றும் சேவைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA weighs approval of a lucrative Alzheimer s drug but benefits are iffy | Nation/World

The Food and Drug Administration’s decision next week whether to approve the first treatment for Alzheimer’s disease highlights a deep division over the drug’s benefits as well as criticism about

Baidu begins charging customers for driverless taxi service

SHARE Chinese tech giant Baidu rolled out its paid driverless taxi service on Sunday, making it the first company to commercialise autonomous driving operations in China. Unlike previous Baidu autonomous driving demonstrations in Beijing, this was the first time there was no safety driver sitting behind the wheel. Instead, a safety member sits in the front passenger seat to deal with any emergencies. Up to 10 Apollo “robotaxis” are now operating simultaneously in an area of about 3 square kilometres, picking up and dropping off passengers at eight stops around Shougang Park in western Beijing. Each ride costs 30 yuan ($4.60), and is open to passengers aged 18 to 60.

FPT Software Joins Hands with Mitsui to Boost Cybersecurity in Japan

Press release content from Business Wire. The AP news staff was not involved in its creation. FPT Software Joins Hands with Mitsui to Boost Cybersecurity in Japan April 20, 2021 GMT FPT Software Chairman Ms. Ha and Mitsui IT & Communication Business Unit GM Mr. Kogiku at the signing ceremony in February 2021. (Photo: Business Wire) FPT Software Chairman Ms. Ha and Mitsui IT & Communication Business Unit GM Mr. Kogiku at the signing ceremony in February 2021. (Photo: Business Wire) HANOI, Vietnam (BUSINESS WIRE) Apr 20, 2021 Vietnam’s leading IT services provider FPT Software has announced its partnership with conglomerate Mitsui & Co., (Mitsui), looking to tap into growing demands for cybersecurity in the Japanese market.

Santhera Reports Interim Results on Convertible Bond Exchange Offer

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Santhera Reports Interim Results on Convertible Bond Exchange Offer Santhera Pharmaceuticals Holding AGApril 20, 2021 GMT NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Pratteln, Switzerland, April 20, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that so far an aggregate principal value of around CHF 39.6 million, or 66% of its CHF 60 Million Convertible Bonds, have been accepted for exchange under the Exchange Offer announced on March 25, 2021. Bondholders who have not yet accepted the Exchange Offer will be able to do so during the additional acceptance period ending on April 27, 2021, 5:00 p.m. CEST. In parallel to the Exchange Offer, voting on the bondholders’ resolution continues.

ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL Erytech Pharma S.A.April 20, 2021 GMT ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL ERYTECH invited by FDA to request a pre-BLA meeting First step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive ALL patients based on the positive results of the NOPHO-sponsored Phase 2 clinical trial Lyon (France) and Cambridge, MA (U.S.), April 20, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the initiation of the process of seeking marketing approval from the U.S. Food and Drug Administration (US FDA) for its lead product candidate eryaspase in patients with acute ly

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.